Gilead Sciences, Inc. (GILD) Shares Bought by Pictet & Cie Europe SA

Pictet & Cie Europe SA increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,641 shares of the biopharmaceutical company’s stock after buying an additional 4,727 shares during the period. Pictet & Cie Europe SA’s holdings in Gilead Sciences were worth $2,084,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of GILD. Wealthcare Advisory Partners LLC bought a new stake in Gilead Sciences during the third quarter valued at $133,000. Certified Advisory Corp bought a new position in shares of Gilead Sciences during the fourth quarter worth about $133,000. Advisors Preferred LLC bought a new position in shares of Gilead Sciences during the first quarter worth about $140,000. Mckinley Capital Management LLC Delaware grew its position in shares of Gilead Sciences by 67.7% during the first quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 860 shares during the last quarter. Finally, Hanson & Doremus Investment Management grew its position in shares of Gilead Sciences by 35.7% during the fourth quarter. Hanson & Doremus Investment Management now owns 2,461 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 648 shares during the last quarter. Institutional investors and hedge funds own 77.72% of the company’s stock.

Shares of Gilead Sciences opened at $67.53 on Friday, according to MarketBeat Ratings. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.84 and a quick ratio of 2.75. The stock has a market capitalization of $88.64 billion, a price-to-earnings ratio of 7.89, a price-to-earnings-growth ratio of -5.93 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.40 billion. During the same period in the previous year, the company posted $2.23 earnings per share. Gilead Sciences’s revenue was down 21.8% compared to the same quarter last year. equities research analysts forecast that Gilead Sciences, Inc. will post 5.75 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Thursday, June 14th. Gilead Sciences’s payout ratio is 26.64%.

Several research firms have recently commented on GILD. BidaskClub lowered shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, May 4th. Barclays lowered their price target on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 2nd. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. Leerink Swann set a $72.00 price target on shares of Gilead Sciences and gave the stock a “market perform” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $88.14.

In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $78.69, for a total transaction of $1,967,250.00. Following the sale, the executive vice president now owns 69,426 shares in the company, valued at approximately $5,463,131.94. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $80.93, for a total value of $472,064.69. The disclosure for this sale can be found here. Insiders sold a total of 226,667 shares of company stock valued at $17,060,854 over the last three months. 1.30% of the stock is owned by corporate insiders.

About Gilead Sciences

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply